Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633435 | 0.83 | MEN1 (0.68) | HPGDALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL1412559 | 0.83 | MEN1 (0.68) | HPGDALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL8211532 | 0.82 | RAB9A (0.71) | GAAHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL10192104 | 0.82 | HSD17B10 (0.54) | HPGDALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL9202177 | 0.82 | HPGD (0.57) | HPGDALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL30599548 | 0.81 | MAPT (0.66) | GAAHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL1188378 | 0.81 | MAPT (0.66) | GAAHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL24218876 | 0.81 | RAB9A (0.51) | GAAHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL8250834 | 0.81 | MEN1 (0.58) | HPGDALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL698170 | 0.81 | HPGD (0.59) | HPGDKMT2AMEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-3535258-B1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| CN-110139862-A | It can be used as the bicyclic heterocycles derivative of ROMK channel inhibitor being substituted | 百时美施贵宝公司 | 2019-08-16 | — | — | CN | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018093569-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | KCNB1, CACNA1E, GRK1 | GAA 4732/4885HPGD 2489/4885ALDH1A1 2047/4885 |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | KCNB1, CACNA1E, GRK1 | GAA 4732/4885HPGD 2489/4885ALDH1A1 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.